Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs.
Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs.
复制标题
DOI：
10.4137/bmi.s29514
复制
发表时间：
2015
影响因子：
3.8
通讯作者：
Durmus N
中科院分区：
文献类型：
--
作者：
Grunig G;Baghdassarian A;Park SH;Pylawka S;Bleck B;Reibman J;Berman-Rosenzweig E;Durmus N
这篇综述讨论了正在研究的生物标志物，它们对表型慢性炎性肺病的有用性，导致肺的结构重塑。综述的重点是哮喘、慢性阻塞性肺疾病（COPD）和肺动脉高压。还讨论了环境暴露的生物标志物和特定类别的生物标志物（非编码RNA，代谢，维生素，凝血和微生物组相关）。讨论了临床使用的生物标志物，正在开发的生物标志物和仍处于研究阶段的生物标志物的例子。我们选择介绍疾病生物标志物发展研究的例子，因为哮喘，COPD和肺动脉高压是不同的实体，尽管它们显然共享炎症和重塑过程。
This review discusses biomarkers that are being researched for their usefulness to phenotype chronic inflammatory lung diseases that cause remodeling of the lung’s architecture. The review focuses on asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. Bio-markers of environmental exposure and specific classes of biomarkers (noncoding RNA, metabolism, vitamin, coagulation, and microbiome related) are also discussed. Examples of biomarkers that are in clinical use, biomarkers that are under development, and biomarkers that are still in the research phase are discussed. We chose to present examples of the research in biomarker development by diseases, because asthma, COPD, and pulmonary hypertension are distinct entities, although they clearly share processes of inflammation and remodeling.